| Optics Unlimited | |
|
277 N Highway 171, Suite 4, Lake Charles, LA 70611-5374 | |
| (337) 478-3810 | |
| (337) 478-6360 |
| Full Name | Optics Unlimited |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 277 N Highway 171, Lake Charles, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356630404 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Optics Unlimited 1717 Oak Park Blvd, Suite 1, Lake Charles, LA 70601-8991 Ph: (337) 478-3810 | Optics Unlimited 277 N Highway 171, Suite 4, Lake Charles, LA 70611-5374 Ph: (337) 478-3810 |
News Archive
As a certified Health IT Quality Solution, Liaison Healthcare's EMR-Link solution has been recognized by Quest Diagnostics as meeting or exceeding advanced industry standards for health IT quality and for providing a streamlined, interoperable solution that enables secure clinical laboratory ordering and results reporting through Quest Diagnostics connectivity solutions.
Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.
A highly renowned obstetrician, professor and researcher who showed that babies born to obese and diabetic women have a higher risk of becoming overweight and developing diabetes or other metabolic health problems later in life, received the March of Dimes 2011 Agnes Higgins award for outstanding achievement in the field of maternal-fetal nutrition.
Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.
In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.
› Verified 9 days ago